Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluate Safety and Efficacy of Daily Oral INM176 in Prostate Patients With Rising Plasma PSA
NCT06600698Phase 2Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- May 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of INM-176 in prostate cancer (PCa), sponsored by Penn State Health Milton S. Hershey Medical Center. Started May 2025; status: recruiting.
02
Drugs
INM-176
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06600698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600698.